Financial Contrast: Ocuphire Pharma (NASDAQ:OCUP) & Emergent BioSolutions (NYSE:EBS)

Ocuphire Pharma (NASDAQ:OCUPGet Free Report) and Emergent BioSolutions (NYSE:EBSGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.


This table compares Ocuphire Pharma and Emergent BioSolutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocuphire Pharma N/A 54.45% 48.96%
Emergent BioSolutions -56.63% -23.29% -10.38%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ocuphire Pharma and Emergent BioSolutions, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocuphire Pharma 0 0 2 0 3.00
Emergent BioSolutions 1 1 1 0 2.00

Ocuphire Pharma currently has a consensus price target of $19.67, indicating a potential upside of 389.22%. Emergent BioSolutions has a consensus price target of $27.75, indicating a potential upside of 571.10%. Given Emergent BioSolutions’ higher probable upside, analysts clearly believe Emergent BioSolutions is more favorable than Ocuphire Pharma.

Earnings and Valuation

This table compares Ocuphire Pharma and Emergent BioSolutions’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocuphire Pharma $45.27 million 1.87 $17.89 million $0.84 4.79
Emergent BioSolutions $1.07 billion 0.20 -$223.80 million ($12.08) -0.34

Ocuphire Pharma has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Ocuphire Pharma, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

17.4% of Ocuphire Pharma shares are owned by institutional investors. Comparatively, 88.3% of Emergent BioSolutions shares are owned by institutional investors. 8.7% of Ocuphire Pharma shares are owned by insiders. Comparatively, 1.9% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Ocuphire Pharma has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.


Ocuphire Pharma beats Emergent BioSolutions on 10 of the 14 factors compared between the two stocks.

About Ocuphire Pharma

(Get Free Report)

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

About Emergent BioSolutions

(Get Free Report)

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with's FREE daily email newsletter.